Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder
Top Cited Papers
- 1 March 2001
- Vol. 57 (3) , 414-421
- https://doi.org/10.1016/s0090-4295(00)01113-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutyninBJU International, 2001
- Muscarinic receptor antagonists in the treatment of overactive bladderUrology, 2000
- Dry mouth with conventional and controlled-release oxybutynin in urinary incontinenceObstetrics & Gynecology, 2000
- Tolterodine, an Effective and Well Tolerated Treatment for Urge Incontinence and Other Overactive Bladder SymptomsClinical Drug Investigation, 2000
- Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive BladderInternational Urogynecology Journal, 1999
- ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCEJournal of Urology, 1999
- Factors involved in the success of antimuscarinic treatmentBJU International, 1999
- Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluationWorld Journal of Urology, 1997
- OxybutyninDrugs & Aging, 1995
- Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivityNeurourology and Urodynamics, 1995